{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:44:25Z","timestamp":1778935465803,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"University of New South Wales (The UNSW Hepatitis C Vaccine Initiative)"},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["630483"],"award-info":[{"award-number":["630483"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Health and Medical Research Council (NHMRC) Dora Lush Postgraduate Scholarship","award":["630754"],"award-info":[{"award-number":["630754"]}]},{"name":"NHMRC Senior Research Fellowships","award":["568614"],"award-info":[{"award-number":["568614"]}]},{"name":"NHMRC Senior Research Fellowships","award":["543135"],"award-info":[{"award-number":["543135"]}]},{"name":"NHMRC Practitioner Fellowship","award":["455355"],"award-info":[{"award-number":["455355"]}]},{"DOI":"10.13039\/100000002","name":"U.S. National Institutes of Health","doi-asserted-by":"crossref","award":["R01DA016017, R01DA031056"],"award-info":[{"award-number":["R01DA016017, R01DA031056"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"U.S. National Institutes of Health","doi-asserted-by":"crossref","award":["HHSN2662040074C"],"award-info":[{"award-number":["HHSN2662040074C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.vaccine.2014.07.091","type":"journal-article","created":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T19:48:19Z","timestamp":1407872899000},"page":"5460-5467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Assessing the feasibility of hepatitis C virus vaccine trials: Results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study"],"prefix":"10.1016","volume":"32","author":[{"given":"Bethany","family":"White","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Madden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Prins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Hellard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Handan","family":"Wand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Page","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Maher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.07.091_bib0005","doi-asserted-by":"crossref","first-page":"7273","DOI":"10.1016\/j.vaccine.2010.08.085","article-title":"Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities","volume":"28","author":"Maher","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0010","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.vaccine.2004.10.002","article-title":"The epidemiological contribution to the preparation of field trials for HIV and STI vaccines: objectives and methods of feasibility studies","volume":"23","author":"Suligoi","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2105\/AJPH.2004.043471","article-title":"Integrating behavioural and social science research into microbicide clinical trials: challenges and opportunities","volume":"96","author":"Tolley","year":"2006","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0020","series-title":"Methodological challenges in biomedical HIV prevention trials","author":"Institute of Medicine","year":"2008"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0025","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0030","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-065X.2010.00977.x","article-title":"Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses","volume":"239","author":"Houghton","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0040","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1586\/erv.11.55","article-title":"Vaccination for hepatitis C virus: closing in on an evasive target","volume":"10","author":"Halliday","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0045","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/nm1353","article-title":"A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees","volume":"12","author":"Folgori","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0050","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1053\/j.gastro.2010.05.077","article-title":"Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins","volume":"139","author":"Dahari","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0055","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1016\/j.vaccine.2010.06.084","article-title":"Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults","volume":"28","author":"Frey","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0060","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in Man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0065","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0070","series-title":"Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees 1995\u20132010","author":"Iversen","year":"2011"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0075","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1753-6405.2007.00007.x","article-title":"High hepatitis C incidence in new injecting drug users: a policy failure?","volume":"31","author":"Maher","year":"2007","journal-title":"Aust N Z J Public Health"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5694\/j.1326-5377.1997.tb138757.x","article-title":"Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990\u20131995","volume":"167","author":"Crofts","year":"1997","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0085","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/j.1360-0443.2006.01543.x","article-title":"Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia","volume":"101","author":"Maher","year":"2006","journal-title":"Addiction"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0090","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.2105\/AJPH.2012.301206","article-title":"Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study","volume":"103","author":"Iversen","year":"2013","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0095","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/aje\/153.7.619","article-title":"Are US populations appropriate for trials of human immunodeficiency virus vaccine?","volume":"153","author":"Seage","year":"2001","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0100","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/00002030-199807000-00015","article-title":"Readiness of high-risk populations in the HIV network for prevention trials to participate in HIV vaccine efficacy trials in the United States","volume":"12","author":"Koblin","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0105","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00126334-200008150-00010","article-title":"Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials, The HIVNET Vaccine Preparedness Study Protocol Team","volume":"24","author":"Koblin","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/dar.12000","article-title":"Increased hepatitis C virus vaccine trial literacy following a brief intervention among people who inject drugs","volume":"32","author":"White","year":"2013","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0115","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1753-6405.2012.00881.x","article-title":"Ongoing susceptibility to hepatitis B virus infection among people who inject drugs in Sydney","volume":"36","author":"White","year":"2012","journal-title":"Aust N Z J Public Health"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0120","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.drugpo.2009.04.004","article-title":"Using ethnographic fieldwork to inform hepatitis C vaccine preparedness studies with people who inject drugs","volume":"21","author":"Maher","year":"2010","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0125","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2307\/800824","article-title":"Targeted sampling-options for the study of hidden populations","volume":"36","author":"Watters","year":"1989","journal-title":"Soc Probl"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0130","series-title":"Stata statistical software: release 12","author":"StataCorp","year":"2011"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0135","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/hep.22534","article-title":"High incidence of hepatitis C virus reinfection in a cohort of injecting drug users","volume":"48","author":"Aitken","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0140","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1086\/605947","article-title":"Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection","volume":"200","author":"Page","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/archpediatrics.2009.241","article-title":"Survival sex work involvement as a primary risk factor for hepatitis C virus acquisition in drug-using youths in a Canadian setting","volume":"164","author":"Shannon","year":"2010","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0150","first-page":"338","article-title":"Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study","author":"Wood","year":"2009","journal-title":"Br Med J"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0155","doi-asserted-by":"crossref","DOI":"10.5694\/mja13.00153","article-title":"Opioid substitution treatment protects against hepatitis C virus acquisition in people who inject drugs: The HITS-c study","author":"White","year":"2014","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0160","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.epidem.2008.10.002","article-title":"Potential impact of vaccination on the hepatitis C virus epidemic in injecting drug users","volume":"1","author":"Hahn","year":"2009","journal-title":"Epidemics"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0165","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/508748","article-title":"Randomized, double blind, placebo controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV1 vaccine among injection drug users in Bangkok, Thailand","volume":"194","author":"Pitisuttithum","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0170","doi-asserted-by":"crossref","first-page":"e25127","DOI":"10.1371\/journal.pone.0025127","article-title":"Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok tenofovir study, Thailand","volume":"6","author":"Martin","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0175","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/aje\/kwn237","article-title":"Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place","volume":"168","author":"Hagan","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0180","series-title":"Women on the edge of crime: crack cocaine and the changing contexts of street-level sex work in New York City","author":"Maher","year":"1998"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0185","volume":"vol. 38","author":"Maher","year":"1998"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0190","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/add.12125","article-title":"Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction?","volume":"108","author":"de Vos","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0195","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1360-0443.2012.03803.x","article-title":"The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users","volume":"107","author":"Bruneau","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0200","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/bmj.317.7156.433","article-title":"Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study","volume":"317","author":"van Beek","year":"1998","journal-title":"Br Med J"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0205","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1053\/jhep.2002.35065","article-title":"Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users","volume":"36","author":"Miller","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0210","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/1471-2458-9-270","article-title":"Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting","volume":"9","author":"Kim","year":"2009","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0215","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1017\/S095026880900212X","article-title":"Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size","volume":"137","author":"Craine","year":"2009","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0220","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.drugalcdep.2011.10.009","article-title":"Motivators and barriers influencing willingness to participate in candidate HCV vaccine trials: perspectives of people who inject drugs","volume":"123","author":"Park","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0225","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals","volume":"58","author":"Martin","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2014.07.091_bib0230","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/COH.0b013e328354131e","article-title":"HIV and viral hepatitis C coinfection in people who inject drugs: implications of new direct acting antivirals for hepatitis C virus treatment","volume":"7","author":"Walsh","year":"2012","journal-title":"Curr Opin HIV AIDS"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14010731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14010731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T04:55:58Z","timestamp":1598158558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14010731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":46,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0264410X14010731"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.091","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the feasibility of hepatitis C virus vaccine trials: Results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}